E-mail page
Print page
Text size:

Consumer Awareness Campaign

As part of our relationship with the medical community, AstraZeneca is helping to inform the public about cholesterol management and atherosclerosis so at-risk patients can have productive conversations about high cholesterol during office visits.

The “Building” Campaign

One tactic we’re using to spread the word is our “Building” campaign. The goal of this initiative is to educate consumers about atherosclerosis, so that they may be able to do something about it as part of a treatment strategy to lower cholesterol.

TV Commercials

Print Advertising

Our commitment to you and your patients continues. In addition to our television and print campaigns, we also offer several patient support programs as well as a consumer education site.

Visit Patient Support Programs

Visit the CRESTOR.com Consumer Site

CRESTOR is indicated¹

As an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.
As an adjunct to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels.
The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined; long-term outcomes studies are currently under way.

CRESTOR is contraindicated¹

In patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers.

Important safety information about CRESTOR¹

Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level, but are increased at the highest dose (40 mg).
CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥ 65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir.
Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.
CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose.
It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (eg, semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume substantial quantities of alcohol.
In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%).⁴

Please see full Prescribing Information for CRESTOR.

CRESTOR is licensed by AstraZeneca from Shionogi & Co LTD, Osaka, Japan.

This product information is intended for
US health care professionals only.

The information on this Web site should not take the place of talking with your doctor or health care professional about how to manage and treat your cholesterol. If you have any questions about your condition, or if you would like more information about CRESTOR or cholesterol, talk to your doctor or pharmacist. Only you and your doctor can decide if CRESTOR is right for you.

Please see full Prescribing Information for CRESTOR
http://switch.atdmt.com/action/nyccre_CRE20070316crestorcomPI_1